Fragment-based Drug Delivery Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Pursuit of Novel Medications to Address Intricate Medical Conditions
   3. Market Restraints
      1. Technical Concerns in Fragment Optimization
      2. Cost and Resource Intensiveness
   4. Market Opportunities
      1. Application of Fragment-based Drug Delivery for the Development of Combination Therapies
   5. Market Trends
      1. Increasing Emphasis on Targeted Therapeutics
      2. Rise in Collaborative Initiatives
5. MARKET SEGMENTATION
   1. By Component
      1. Fragment Screening
         1. Biophysical Techniques
            1. NMR Spectroscopy
            2. Differential Scanning Fluorimetry (DSF) Assay
            3. Fluorescence Polarization
            4. Isothermal Titration Calorimetry
            5. X-ray Crystallography
            6. Surface Plasmon Resonance (SPR)
            7. Bilayer Interferometry
            8. Mass Spectrometry (MS)
            9. Capillary Electrophoresis
            10. Weak Affinity Chromatography (WAC – HPLC – UV/MS)
            11. Other Assay (biochemical)
         2. Non-biophysical Techniques
      2. Fragment Optimization
   2. By Application
      1. Oncology
      2. Central Nervous System (CNS) Disorders
      3. Infectious Diseases
      4. Cardiovascular Diseases
      5. Metabolic Disorders
      6. Inflammation & Autoimmune Diseases
   3. By End User
      1. Academic & Research Institutions
      2. Pharmaceutical & Biotechnology Companies
      3. Contract Research Organizations (CROs)
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Alveus Pharmaceuticals Pvt. Ltd.
      2. Astex Pharmaceuticals
      3. Beactica AB
      4. Charles River Laboratories International, Inc.
      5. Crown Bioscience, Inc.
      6. Evotec AG
      7. Emerald BioStructures, Inc.
      8. Kinetic Discovery Limited
      9. Proteros Fragments GmbH
      10. Sprint Bioscience
      11. Sygnature Discovery
      12. Structure Based Design, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global fragment-based drug deliverymarket?

The global market of fragment-based drug delivery is projected to reach USD 3.12Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global fragment-based drug deliverymarket?

The global fragment-based drug delivery market has an estimated annual growth rate of 11% .

Q.3. What are the recent trends of fragment-based drug deliverymarket?

Increasing emphasis on targeted therapeutics and rise in collaborative initiativesare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in fragment-based drug delivery?

The major companies profiled in this report include Alveus Pharmaceuticals Pvt. Ltd., Astex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Evotec AG, Emerald BioStructures, Inc., Kinetic Discovery Limited, Proteros Fragments GmbH, Sprint Bioscience, Sygnature Discovery, Structure Based Design, Inc., among others.

Q.5. Which region is estimated to held highest CAGR infragment-based drug deliverymarket?

North America is estimated to hold biggest share in the market for fragment-based drug delivery.